跳至主要内容
临床试验/NL-OMON46302
NL-OMON46302已完成不适用

Platelet reactivity, inflammation and endothelial dysfunction during and after exacerbation in chronic obstructive pulmonary disease (COPD) patients - IMPROVE study

Gelre Ziekenhuizen0 个研究点目标入组 76 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
76

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • * Acute exacerbation of COPD, defined as an as an acute worsening of respiratory symptoms that results in additional therapy (COPD Gold 2018)
  • * >40 years oud
  • * Moderate to severe (>Gold 2) airflow limitation detected by spirometry (FEV1/FVC ratio < 70%, FEV1 < 80%) and clinical diagnosis of COPD confirmed by a pulmonologist.
  • * Current or former smoker, with *10 pack years of smoking

排除标准

  • * Suspected or proven alternative diagnosis for the acute deterioration in symptoms such as pneumonia, pulmonary embolism or heart failure
  • * Use of anti-coagulants, aspirin or other platelet function inhibitors
  • * Use of statins or ACE inhibitors
  • * Concomitant diagnosis of asthma or other respiratory disease
  • * Diagnosis of hepatic and/or renal failure
  • * Chronic inflammatory diseases, such as rheumatoid arthritis, psoriasis, inflammatory bowel diseases, systemic lupus erythematous (SLE), diabetes mellitus (DM)
  • * Malignancies (excluding basal cell carcinoma of the skin)

研究者

相似试验